UPMC Hamot, formerly known as Hamot Medical Center, is a 446-bed hospital and a tertiary-care medical facility located in Erie, Pennsylvania. It is one of the largest employers in the Erie region. The complex features several large buildings, including a heart institute. It was founded in 1881.

There are 412 beds in UPMC Hamot.

During the past decade, UPMC Hamot conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 13 clinical trials were completed, i.e. on average, 56.5% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 9 clinical trials were completed. i.e. 81.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UPMC Hamot" #1 sponsor was "National Cancer Institute (NCI)" with 5 trials, followed by "Abbott Medical Devices" with 2 trials sponsored, "Alliance for Clinical Trials in Oncology" with 2 trials sponsored, "Bayer" with 2 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UPMC Hamot" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Alberta Innovation and Science" with 1 trials as a collaborator, "American Heart Association" with 1 trials as a collaborator and "Angiotech Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "UPMC Hamot" are "Acute Myocardial Infarction" (3 trials), "Coronary Artery Disease" (3 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials), "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7" (3 trials) and "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials). Many other conditions were trialed in "UPMC Hamot" in a lesser frequency.

Most popular intervention types in "UPMC Hamot" are "Drug" (17 trials), "Device" (14 trials), "Other" (9 trials), "Biological" (7 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (5 trials), "Cisplatin" (3 trials), "Clinical Observation" (3 trials), "Crizotinib" (3 trials) and "Gemcitabine Hydrochloride" (3 trials). Other intervention names were less common.

The vast majority of trials in "UPMC Hamot" are 34 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UPMC Hamot". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in UPMC Hamot, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in UPMC Hamot, 1 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 12 trials that are defined as “Not Applicable".